![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif)
naltrexone hydrochloride The hydrochloride salt of naltrexone, a noroxymorphone derivative with competitive opioid antagonistic activity. Naltrexone and its metabolite 6-beta-naltrexol reverse the effects of opioids by binding to various opioid receptors in the central nervous system CNS), including the mu-, kappa- and gamma-opioid receptors; opioid effects of analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence are inhibited. Naltrexone is longer-acting and more potent compared to naloxone. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif)
US brand names: | ![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif) | Depade Revia | | ![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure name: | ![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif) | (5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride | | ![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090114231010im_/http://www.cancer.gov/images/spacer.gif) |